About Event
Welcome to the 8th International Neoantigen Summit!
As positive clinical data continues to emerge, join pioneering Directors, VPs and C-Level Executives and industry colleagues to turbocharge neoantigen vaccines and therapies.
Powering your candidates progression, the 8th International Neoantigen Summit returns to cover everything from selecting the most immunogenic neoantigens, overcoming translational hurdles to accurately monitoring immune response and efficiently manufacturing vaccines and therapies.
Offering data driven insights, case study presentations and informative discussions uncover efficacious, clinically successful therapies with the power to elicit a durable immune response in patients.
Brand-New 2025 Sessions:
UNPUBLISHED DATA: Phase 2 study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma
(Find full session details in the brochure here)
- Daniela Kleine-Kohlbrecher, Project Director Immuno-oncology, Evaxion Biotech
Round Table Discussion: Lessons on Clinical Design, Patient Selection & Measuring Efficacy from Clinical Stage Trials
(Find full session details in the brochure here)
Ulrike Gnag-Vogt, Senior Vice President, Clinical Development, CureVac
Panel Discussion: Validating Immunogenicity of Neoantigens & Establishing a Consensus on Selecting Optimal Neoantigen Targets to Generate an Efficacious Immune Response
(Find full session details in the brochure here)
- AilseBio, CureVac, Anocca, Epitopea
BNT221: A First-in-Human Trial with a Personalized, Autologous Neoantigen-Specific T cell Therapy in Metastatic Melanoma
(Find full session details in the brochure here)
- Sebastian Klobuch, Medical Oncologist, Netherlands Cancer Institute
What Are Your Industry Colleagues Excited About?
What You Missed:
Top 5 Reasons to Attend:
Power the progression of your neoantigen pipeline into efficacious therapies by developing robust protocols, with lessons from Transgene, Nouscom & Geneos Therapeutics.
Expand your immune monitoring toolbox and ensure the development of durable, tolerable and targeted therapies with insight from Precision Biologics, Evaxion Biotech & Institut Curie.
Maximise the efficacy of your neoantigen cancer vaccines and therapies by identifying highly immunogenic antigens, with learnings from AstraZeneca, CureVac & Anocca.
Achieve the full therapeutic potential of neoantigen medicines by exploring synergistic combination strategies to overcome tumour resistance, with clinical insight from Scancell & VacV Biotherapeutics.
Unlock neoantigen therapies for more patients by exploring shared neoantigens and improving time and cost-efficiency of production, with lessons from Genevation, Epitopea and AilseBio.